Floatz logo

Ipatasertib

Urinary Bladder Carcinoma

National Cancer Institute (NCI)Small moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
89/ 100

Competitive context

120 Active assets in the Urinary Bladder Carcinoma cohort.

Asset / SponsorPhaseRating
Cis-Diamminedichloroplatinum Ii
G1 Therapeutics, Inc.
Phase 3BBB
Trastuzumab
NKGen Biotech, Inc.
Phase 2BB
Carboplatin
G1 Therapeutics, Inc.
Phase 3BB
Cyclophosphamide
Beijing Biotech
Phase 3BB
Vinblastine
University of Southern California
Phase 3BB

View all 50 →

Same molecule, other indications

Ipatasertib is also rated in:

estrogen-receptor positive breast cancerActive
BB
Indicative · Phase 2
64 / 100
View asset →
breast cancerActive
B
Indicative · Phase 3
60 / 100
View asset →
metastatic prostate carcinomaActive
B
Indicative · Phase 3
60 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →